(Q40568409)

21 September 2017

title

The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus (English)

1 reference

neuropsychiatric systemic lupus erythematosus

21 September 2017

main subject

0 references

author name string

C Michael Neuwelt

series ordinal

1

1 reference

21 September 2017

publication date

1 April 2003

1 reference

Therapeutic Apheresis and Dialysis

21 September 2017

published in

1 reference

21 September 2017

volume

7

1 reference

21 September 2017

issue

2

1 reference

21 September 2017

page(s)

173-182

1 reference

Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis.

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00032.X

Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00032.X

Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00032.X

Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00032.X

Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00032.X

Novel therapeutic agents for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00032.X

Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00032.X

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00032.X

A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00032.X

Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00032.X

Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00032.X

Multiple sclerosis: the importance of early recognition and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00032.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00032.X

Updating the American College of Rheumatology criteria for systemic lupus erythematosus: comment on the letter by Hochberg

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00032.X

10.1046/J.1526-0968.2003.00032.X

21 January 2018

Identifiers

DOI

1 reference

21 September 2017

1 reference